|
| 36273799 | Long-term Gastrointestinal Sequelae Following COVID-19: A Prospective Follow-up Cohort Study. | Clin Gastroenterol Hepatol | 2023 |
| 36273799 | Long-term Gastrointestinal Sequelae Following COVID-19: A Prospective Follow-up Cohort Study. | Clin Gastroenterol Hepatol | 2023 |
| 36426653 | Early circulating tumor DNA dynamics as a pan-tumor biomarker for long-term clinical outcome in patients treated with durvalumab and tremelimumab. | Mol Oncol | 2023 |
| 37608704 | Myelodysplastic syndrome and multiple solid tumours in an individual with compound heterozygous deleterious FANCM variants: A case report and review of the literature. | Br J Haematol | 2023 |
| 37845394 | Ligand-dependent hedgehog signaling maintains an undifferentiated, malignant osteosarcoma phenotype. | Oncogene | 2023 |
| 37596165 | Genetically inferred birthweight, height, and puberty timing and risk of osteosarcoma. | Cancer Epidemiol | 2023 |
| 37820553 | Modified study designs to expand treatment options in personalised oncology: a multistakeholder view. | Eur J Cancer | 2023 |
| 36656928 | Heritable defects in telomere and mitotic function selectively predispose to sarcomas. | Science | 2023 |
| 37210765 | Family communication and results disclosure after germline sequencing: A mixed methods study. | Patient Educ Couns | 2023 |
| 37365284 | A signal-seeking Phase 2 study of olaparib and durvalumab in advanced solid cancers with homologous recombination repair gene alterations. | Br J Cancer | 2023 |
| 37171781 | Low prevalence of Clostridioides difficile infection in acute severe ulcerative colitis: A retrospective cohort study from northern India. | Indian J Gastroenterol | 2023 |
| 36926698 | Serum albumin is the strongest predictor of anti-tumor necrosis factor nonresponse in inflammatory bowel disease in resource-constrained regions lacking therapeutic drug monitoring. | Intest Res | 2023 |
| 37424386 | Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials. | Int J Cancer | 2023 |
| 36599878 | Precision medicine: affording the successes of science. | NPJ Precis Oncol | 2023 |
| 37596165 | Genetically inferred birthweight, height, and puberty timing and risk of osteosarcoma. | Cancer Epidemiol | 2023 |
| 37845394 | Ligand-dependent hedgehog signaling maintains an undifferentiated, malignant osteosarcoma phenotype. | Oncogene | 2023 |
| 37608704 | Myelodysplastic syndrome and multiple solid tumours in an individual with compound heterozygous deleterious FANCM variants: A case report and review of the literature. | Br J Haematol | 2023 |
| 37820553 | Modified study designs to expand treatment options in personalised oncology: a multistakeholder view. | Eur J Cancer | 2023 |
| 37424386 | Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials. | Int J Cancer | 2023 |
| 37210765 | Family communication and results disclosure after germline sequencing: A mixed methods study. | Patient Educ Couns | 2023 |
| 37171781 | Low prevalence of Clostridioides difficile infection in acute severe ulcerative colitis: A retrospective cohort study from northern India. | Indian J Gastroenterol | 2023 |
| 37365284 | A signal-seeking Phase 2 study of olaparib and durvalumab in advanced solid cancers with homologous recombination repair gene alterations. | Br J Cancer | 2023 |
| 36926698 | Serum albumin is the strongest predictor of anti-tumor necrosis factor nonresponse in inflammatory bowel disease in resource-constrained regions lacking therapeutic drug monitoring. | Intest Res | 2023 |
| 36656928 | Heritable defects in telomere and mitotic function selectively predispose to sarcomas. | Science | 2023 |
| 36426653 | Early circulating tumor DNA dynamics as a pan-tumor biomarker for long-term clinical outcome in patients treated with durvalumab and tremelimumab. | Mol Oncol | 2023 |
| 36599878 | Precision medicine: affording the successes of science. | NPJ Precis Oncol | 2023 |
| 34016496 | Effectively communicating comprehensive tumor genomic profiling results: Mitigating uncertainty for advanced cancer patients. | Patient Educ Couns | 2022 |
| 35705558 | Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma. | Nat Commun | 2022 |
| 35440717 | Delivering precision oncology to patients with cancer. | Nat Med | 2022 |
| 35809119 | Return of comprehensive tumour genomic profiling results to advanced cancer patients: a qualitative study. | Support Care Cancer | 2022 |
| 35487418 | Psychological predictors of cancer patients' and their relatives' attitudes towards the return of genomic sequencing results. | Eur J Med Genet | 2022 |
| 35674123 | Challenges of Conducting Value Assessment for Comprehensive Genomic Profiling. | Int J Technol Assess Health Care | 2022 |
| 36264554 | Practical Considerations for the Use of Circulating Tumor DNA in the Treatment of Patients With Cancer: A Narrative Review. | JAMA Oncol | 2022 |
| 35604703 | Psychological outcomes in advanced cancer patients after receiving genomic tumor profiling results. | Health Psychol | 2022 |
| 36455193 | Clinical Response to Seribantumab, an Anti-Human Epidermal Growth Factor Receptor-3 Immunoglobulin 2 Monoclonal Antibody, in a Patient With Metastatic Pancreatic Ductal Adenocarcinoma Harboring an <i>NRG1</i> Fusion. | JCO Precis Oncol | 2022 |
| 34016496 | Effectively communicating comprehensive tumor genomic profiling results: Mitigating uncertainty for advanced cancer patients. | Patient Educ Couns | 2022 |
| 34218500 | Value of whole-genome sequencing to Australian cancer patients and their first-degree relatives participating in a genomic sequencing study. | J Genet Couns | 2022 |
| 34687117 | Rare germline variants in childhood cancer patients suspected of genetic predisposition to cancer. | Genes Chromosomes Cancer | 2022 |
| 35277654 | Preferences for return of germline genome sequencing results for cancer patients and their genetic relatives in a research setting. | Eur J Hum Genet | 2022 |
| 34755933 | Psychological predictors of advanced cancer patients' preferences for return of results from comprehensive tumor genomic profiling. | Am J Med Genet A | 2022 |
| 35153126 | Psychological impact of comprehensive tumor genomic profiling results for advanced cancer patients. | Patient Educ Couns | 2022 |
| 35809119 | Return of comprehensive tumour genomic profiling results to advanced cancer patients: a qualitative study. | Support Care Cancer | 2022 |
| 35440717 | Delivering precision oncology to patients with cancer. | Nat Med | 2022 |
| 35705558 | Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma. | Nat Commun | 2022 |
| 35674123 | Challenges of Conducting Value Assessment for Comprehensive Genomic Profiling. | Int J Technol Assess Health Care | 2022 |
| 35604703 | Psychological outcomes in advanced cancer patients after receiving genomic tumor profiling results. | Health Psychol | 2022 |
| 35487418 | Psychological predictors of cancer patients' and their relatives' attitudes towards the return of genomic sequencing results. | Eur J Med Genet | 2022 |
| 36455193 | Clinical Response to Seribantumab, an Anti-Human Epidermal Growth Factor Receptor-3 Immunoglobulin 2 Monoclonal Antibody, in a Patient With Metastatic Pancreatic Ductal Adenocarcinoma Harboring an <i>NRG1</i> Fusion. | JCO Precis Oncol | 2022 |
| 36264554 | Practical Considerations for the Use of Circulating Tumor DNA in the Treatment of Patients With Cancer: A Narrative Review. | JAMA Oncol | 2022 |
| 35153126 | Psychological impact of comprehensive tumor genomic profiling results for advanced cancer patients. | Patient Educ Couns | 2022 |